Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus GVS.
AMIKACIN SULFATE vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
GVS is not a recognized drug. No mechanism of action available.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic